1. Berek JS, Kehoe ST, Kumar L, Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology & Obstetrics. 2018; 143:59-78.
2. Barbolina MV: Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma. Cancers (Basel). 2018; 10(11).
3. Guth U, Huang DJ, Bauer G, Stieger M, Wight E, Singer G: Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer. 2007; 110(6):1272-1280.
4. Van Berckelaer C, Brouwers AJ, Peeters DJ, Tjalma W, Trinh XB, van Dam PA: Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. Eur J Surg Oncol. 2016; 42(12):1772-1779.
5. Bachmann C, Bachmann R, Fend F, Wallwiener D: Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment. J Cancer. 2016; 7(15):2241-2246.
6. Matsuo K, Sheridan TB, Yoshino K, Miyake T, Hew KE, Im DD et al: Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med. 2012; 1(2):156-164.
7. Li J, Li S, Chen R, Lu X: Increased risk of poor survival in ovarian cancer patients with high expression of SNAI2 and lymphovascular space invasion. Oncotarget. 2017; 8(6):9672-9685.
8. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T et al: Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014; 26(1):77-91.
9. Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I et al: curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford). 2013; 2013:bat013.
10. Yu G, Wang LG, Han Y, He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012; 16(5):284-287.
11. Hanzelmann S, Castelo R, Guinney J: GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7.
12. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612.
13. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T et al: Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30(5):413-421.
14. Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F et al: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218.
15. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS et al: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110.
16. Yuzhalin AE, Urbonas T, Silva MA, Muschel RJ, Gordon-Weeks AN: A core matrisome gene signature predicts cancer outcome. Br J Cancer. 2018; 118(3):435-440.
17. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14(16):5198-5208.
18. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
19. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5):392-401.
20. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV et al: Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012; 22(5):571-584.
21. Cai J, Tang H, Xu L, Wang X, Yang C, Ruan S et al: Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis. 2012; 33(1):20-29.
22. Huang RY, Wong MK, Tan TZ, Kuay KT, Ng AH, Chung VY et al: An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 2013; 4:e915.
23. Coffman LG, Burgos-Ojeda D, Wu R, Cho K, Bai S, Buckanovich RJ: New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl Res. 2016; 175:92-102.e102.
24. Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W et al: Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol Oncol. 2018; 150(3):460-465.
25. Figueras A, Alsina-Sanchis E, Lahiguera A, Abreu M, Muinelo-Romay L, Moreno-Bueno G et al: A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. Mol Cancer Ther. 2018; 17(2):532-543.
26. Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY et al: Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol. 2015; 139(3):394-400.
27. Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X et al: A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014; 20(3):711-723.
28. Madar S, Goldstein I, Rotter V: 'Cancer associated fibroblasts'--more than meets the eye. Trends Mol Med. 2013; 19(8):447-453.
29. Dasari S, Fang Y, Mitra AK: Cancer Associated Fibroblasts: Naughty Neighbors That Drive Ovarian Cancer Progression. Cancers (Basel). 2018; 10(11).
30. Valkenburg KC, de Groot AE, Pienta KJ: Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018; 15(6):366-381.
31. Zhang Y, Tang H, Cai J, Zhang T, Guo J, Feng D et al: Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett. 2011; 303(1):47-55.
32. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W et al: A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003; 9(5):1639-1647.
33. Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C et al: Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003; 26(1):44-48.
34. Colak S, Ten Dijke P: Targeting TGF-beta Signaling in Cancer. Trends Cancer. 2017; 3(1):56-71.
35. Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA et al: POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014; 132(2):334-342.
36. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V et al: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 15(1):68-74.
37. Kim H, Watkinson J, Varadan V, Anastassiou D: Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics. 2010; 3:51